330 related articles for article (PubMed ID: 30293110)
21. Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin.
Markvardsen LH; Vaeggemose M; Ringgaard S; Andersen H
Neuroradiology; 2016 Aug; 58(8):745-52. PubMed ID: 27114080
[TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.
Hahn AF; Bolton CF; Zochodne D; Feasby TE
Brain; 1996 Aug; 119 ( Pt 4)():1067-77. PubMed ID: 8813271
[TBL] [Abstract][Full Text] [Related]
23. Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.
Mathis S; Vallat JM; Magy L
Immunotherapy; 2016 Feb; 8(2):165-78. PubMed ID: 26809024
[TBL] [Abstract][Full Text] [Related]
24. A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy.
Al-Zuhairy A; Sindrup SH; Andersen H; Jakobsen J
Muscle Nerve; 2020 Mar; 61(3):316-324. PubMed ID: 31793666
[TBL] [Abstract][Full Text] [Related]
25. ELectron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody.
Kuwahara M; Suzuki H; Oka N; Ogata H; Yanagimoto S; Sadakane S; Fukumoto Y; Yamana M; Yuhara Y; Yoshikawa K; Morikawa M; Kawai S; Okazaki M; Tsujimoto T; Kira JI; Kusunoki S
Muscle Nerve; 2018 Mar; 57(3):498-502. PubMed ID: 28796305
[TBL] [Abstract][Full Text] [Related]
26. Long-term effects of intravenous immunoglobulin in CIDP.
Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.
Querol L; Rojas-Garcia R; Casasnovas C; Sedano MJ; Muñoz-Blanco JL; Alberti MA; Paradas C; Sevilla T; Pardo J; Capablo JL; Sivera R; Guerrero A; Gutierrez-Rivas E; Illa I
Muscle Nerve; 2013 Dec; 48(6):870-6. PubMed ID: 23512566
[TBL] [Abstract][Full Text] [Related]
28. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids.
Muley SA; Kelkar P; Parry GJ
Arch Neurol; 2008 Nov; 65(11):1460-4. PubMed ID: 19001164
[TBL] [Abstract][Full Text] [Related]
29. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
[TBL] [Abstract][Full Text] [Related]
30. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Dyck PJ; Taylor BV; Davies JL; Mauermann ML; Litchy WJ; Klein CJ; Dyck PJ
Muscle Nerve; 2015 Oct; 52(4):488-97. PubMed ID: 25976871
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of long-term prednisone therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP): a retrospective cohort study.
López-Hernández JC; Mercado-Pompa A; Pérez-Torres T; Galnares-Olalde JA; Vargas-Cañas ES
Rev Neurol; 2021 Oct; 73(8):275-281. PubMed ID: 34617581
[TBL] [Abstract][Full Text] [Related]
32. Nerve echogenicity and intranerve CSA variability in high-resolution nerve ultrasound (HRUS) in chronic inflammatory demyelinating polyneuropathy (CIDP).
Fisse AL; Pitarokoili K; Motte J; Gamber D; Kerasnoudis A; Gold R; Yoon MS
J Neurol; 2019 Feb; 266(2):468-475. PubMed ID: 30554264
[TBL] [Abstract][Full Text] [Related]
33. Interferon beta-1a as an investigational treatment for CIDP.
Vallat JM; Hahn AF; Léger JM; Cros DP; Magy L; Tabaraud F; Bouche P; Preux PM
Neurology; 2003 Apr; 60(8 Suppl 3):S23-8. PubMed ID: 12707419
[TBL] [Abstract][Full Text] [Related]
34. Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
Vo ML; Chin RL; Miranda C; Latov N
Muscle Nerve; 2017 Oct; 56(4):732-736. PubMed ID: 28085193
[TBL] [Abstract][Full Text] [Related]
35. A distinct subgroup of chronic inflammatory demyelinating polyneuropathy with CNS demyelination and a favorable response to immunotherapy.
Pineda AA; Ogata K; Osoegawa M; Murai H; Shigeto H; Yoshiura T; Tobimatsu S; Kira J
J Neurol Sci; 2007 Apr; 255(1-2):1-6. PubMed ID: 17306302
[TBL] [Abstract][Full Text] [Related]
36. Axonal loss in patients with inflammatory demyelinating polyneuropathy as determined by motor unit number estimation and MUNIX.
Paramanathan S; Tankisi H; Andersen H; Fuglsang-Frederiksen A
Clin Neurophysiol; 2016 Jan; 127(1):898-904. PubMed ID: 26049677
[TBL] [Abstract][Full Text] [Related]
37. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.
Kuwabara S; Misawa S; Mori M; Tamura N; Kubota M; Hattori T
J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):66-70. PubMed ID: 16361595
[TBL] [Abstract][Full Text] [Related]
38. [Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy].
Kanbayashi T; Sonoo M
Brain Nerve; 2015 Nov; 67(11):1388-96. PubMed ID: 26560954
[TBL] [Abstract][Full Text] [Related]
39. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.
Harbo T; Andersen H; Jakobsen J
Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876
[TBL] [Abstract][Full Text] [Related]
40. Octagam
Wietek S
Neurodegener Dis Manag; 2018 Aug; 8(4):227-231. PubMed ID: 29517417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
